Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.
|Poll|May 11, 2015
Check Your Bipolar Acumen: Question #3
Advertisement
Patients with bipolar disorder experience a substantial burden of medical and psychiatric comorbidities. A recent study in the British Journal of Psychiatry sheds light on the most prevalent medical conditions among persons with bipolar disorder.
Which of these was not one of the most common conditions in patients with BP?
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Psychiatric Times
1
Dementia and the Tuberculosis Vaccine: Reduced Tau Burden With Administration in Mice
2
GLP-1 Receptor Agonists May Reinforce Restriction in Patients With Eating Disorders
3
ALKS 7290 for Adjunctive Treatment for MDD Enters Phase 2 Study
4
October 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
5